# Aimed Bio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/aimed-bio

- Industry: Biotechnology
- Headquarters: Seoul, South Korea
- Website: www.aimedbio.com/
- Total disclosed funding: $29M
- Latest round: Series B (Jul 31, 2024)
- Investors on record: 6

## About

Based in Seoul, South Korea, and founded in 2018, Aimed Bio Inc. operates as a biotechnology company that uses big data technologies to develop therapy and medication for cancer-related problems. The company was founded by its chairman and CTO Do-Hyun Nam as a spin-off of Samsung Medical Center (SMC). In June 2025, Aimed Bio Inc. raised KRW 51.1 billion in pre-IPO funding co-led by returning investors InterVest, DS Asset Management, Samsung Life Public Welfare Foundation, and SMB Investment Partners. New investor Mirae Asset Securities also participated in the round.

The firm offers a brain-oriented multi-disciplinary platform that uses big data technologies to develop therapy and medication for cancer-related problems. It offers therapeutic solutions to patients with serious brain diseases, including neuro-oncological and -degenerative diseases. The brain-oriented multi-disciplinary solution offered includes a BBB crossing platform, patient-derived model platform, multi-omics platform, brain immune modulation platform, and antibody-drug conjugate platform.

## Funding rounds

- Series B, Jul 31, 2024, $29M — InterVest, Samsung Venture Investment, Yuhan Corporation, Mint Venture Partners, Samsung Life Public Welfare Foundation, DS Asset Management
- Series A, Sep 13, 2023 — Samsung Venture Investment

## Investors

- Samsung Venture Investment (https://capitalatlas.ai/funds/samsung-venture-investment) — Series A, Series B
- InterVest (https://capitalatlas.ai/funds/intervest) — Series B
- Yuhan Corporation — Series B
- Mint Venture Partners (https://capitalatlas.ai/funds/mint-venture-partners) — Series B
- Samsung Life Public Welfare Foundation — Series B
- DS Asset Management (https://capitalatlas.ai/funds/ds-asset-management) — Series B